Loading provider…
Loading provider…
Dermatology Physician in Orange, CA
NPI: 1346415437Primary Practice Location
UNIVERSITY OF CALIFORNIA IRVINE MEDICAL CENTER
101 The City Dr S, Orange, CA
Primary Employer
UCI Department of Dermatology
ucihealth.org
HQ Phone
Get M.D. PH.D. Natasha's Phone Numberphone_androidMobile
Get M.D. PH.D. Natasha's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
OH State Medical License
CA State Medical License
2014 - 2025
HI State Medical License
2014 - 2016
OH State Medical License
2007 - 2016

American Board of Dermatology
Dermatology

American Board of Dermatology
Dermatopathology
Mayo Clinic Alix School of Medicine - Rochester
college.mayo.edu
Medical School
Until 2007
Cleveland Clinic Foundation
Fellowship • Dermatopathology
2012 - 2013
Residency • Dermatology
2007 - 2012
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 143 | 239 |
| 2 | 17110Destruction of up to 14 skin growths | 80 | 111 |
| 3 | 17000Destruction of skin growth | 79 | 111 |
| 4 | 17003Destruction of 2-14 skin growths | 74 | 481 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 68 | 99 |
Hypopigmentation of the Eyebrows in Frontal Fibrosing Alopecia.
Authors: Rosalynn Conic, Wilma Bergfeld, Edward Maytin
Journal: Skin Appendage Disord
Publication Date: 2021-02-10
Vitamin D Status in Scarring and Non-Scarring Alopecia
Lead Sponsor: University of California, Irvine
Intervention / Treatment: COMBINATION_PRODUCT: calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Baricitinib